Nuvalent announced the initiation of the Phase 2 portion of ALKOVE-1, its Phase 1/2 clinical trial of NVL-655 for patients with ALK-positive non-small cell lung cancer, or NSCLC, and other solid tumors, following alignment with the FDA on a recommended Phase 2 dose, or RP2D, of 150 mg once daily, or QD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NUVL:
